Novartis to acquire Avidity Biosciences for $12 billion
PositiveFinancial Markets

Novartis has announced its plan to acquire Avidity Biosciences for $12 billion, a move that highlights its commitment to expanding its portfolio in the biotechnology sector. This acquisition is significant as it allows Novartis to enhance its capabilities in developing innovative therapies, particularly in the field of RNA-targeted treatments. The deal reflects the growing trend of large pharmaceutical companies investing in biotech firms to stay competitive and meet the evolving needs of patients.
— Curated by the World Pulse Now AI Editorial System








